Table 3 Logistic regression of dose escalation status and treatment year adjusting for potential confounders in NODA during Period 1 (2004–2010)
NODA 2004–2010 (N = 1408) | ||||
|---|---|---|---|---|
Study sample characteristics | Escalated dose | Standard dose | Escalated vs standard dose | |
No. (%) | No. (%) | Adjusted OR (95% CI) | P* | |
Treatment year | 1.16 (1.09–1.25) | <0.0001 | ||
Age | ||||
≤ 67 yo | 197 (52) | 446 (49) | ref | |
> 67 yo | 181 (48) | 466 (51) | 0.92 (0.72–1.18) | 0.52 |
Sex | ||||
Male | 230 (61) | 520 (57) | ref | |
Female | 148 (39) | 392 (43) | 0.82 (0.64–1.06) | 0.14 |
Race | ||||
White | 339 (90) | 788 (86) | ref | |
Non-white | 37 (10) | 115 (13) | 0.61 (0.40–0.90) | 0.01 |
Missing | 2 (<1) | 9 (1) | Not included | |
Histology | ||||
Squamous | 168 (44) | 351 (38) | ref | |
Non-Squamous | 210 (56) | 561 (62) | 0.85 (0.66–1.10) | 0.20 |
Derived AJCC v6 T-stage | ||||
T0-2 | 263 (70) | 599 (66) | ref | |
T3 | 110 (29) | 282 (31) | 0.87 (0.66–1.14) | 0.30 |
Missing | 5 (1) | 31 (3) | Not included | |
Charlson/Deyo Score | ||||
0 | 237 (63) | 662 (68) | ref | |
1 | 109 (29) | 210 (24) | 1.45 (1.09–1.93) | 0.01 |
2+ | 32 (8) | 76 (8) | 1.10 (0.69–1.73) | 0.46 |
Hospital typea | ||||
Community | 278 (74) | 769 (84) | ref | |
Academic | 100 (26) | 143 (16) | 2.33 (1.70–3.20) | <.0001 |
Hospital settinga | ||||
Metro | 302 (80) | 763 (84) | ||
Non-metro | 76 (20) | 149 (16) | 1.62 (1.16–2.24) | 0.0046 |